The allele frequency of mutations measured through DNA sequencing was compared with the percentage of CD19-negative tumor cells by flow cytometry in patients' samples and showed most tumor cells in the relapsed sample contained a CD19 loss-of-function mutation. This evidence concerns the gene CD19 and neoplasm.